PeterD.EisenbergMD

Oncology • San Anselmo, CA

Physician

Join to view full profile

Dr. Eisenberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Eisenberg's full profile

Already have an account?

Office
50 Yolanda Dr
San Anselmo, CA 94960
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1976 - 1978
University of Florida College of Medicine JacksonvilleResidency, Internal Medicine, 1974 - 1975
Sparrow HospitalResidency, Internal Medicine, 1973 - 1974
University of Florida College of Medicine JacksonvilleInternship, Internal Medicine, 1972 - 1973
Drexel University College of MedicineClass of 1972

Certifications & Licensure

MI State Medical License Current
CA State Medical License 1976 - 2025
FL State Medical License 1974 - 1989
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2008
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma Start of enrollment: 2007 Feb 01
Terminated
Phase 2
Safety and Efficacy Study of Glufosfamide in Ovarian Cancer Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2007 Jul 01
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Start of enrollment: 2010 Aug 11
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Start of enrollment: 2011 Jan 01
Completed
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 1
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) Start of enrollment: 2013 Dec 13
Terminated
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Start of enrollment: 2020 May 28
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

51 citations
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
Daniel V.T. Catenacci, Anteneh Tesfaye, Mohamed Tejani, Eric Cheung, Peter D. Eisenberg, Aaron Scott, Clarence Eng, James Hnatyszyn, Neyssa Marina, Janine Powers, Zev ...> ;Future Oncology. 2019 May 16
111 citations
A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
David Smith, Peter D. Eisenberg, George M Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert Joseph Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir I. Sikic> ;Clinical Cancer Research. 2014 Dec 15
4 citations
Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop
Erin Balogh, Peter B. Bach, Peter D. Eisenberg, Patricia A. Ganz, Robert J. Green, Jessie C. Gruman, Sharyl J. Nass, Lee N. Newcomer, Scott D. Ramsey, Joanne E. Schott...> ;Journal of Oncology Practice. 2013 Nov 1
51 citations
Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
Lee S. Schwartzberg, Kurt W. Tauer, Robert Hermann, Grace Makari-Judson, Claudine Isaacs, J. Thaddeus Beck, Virginia G. Kaklamani, Edward J. Stepanski, Hope S. Rugo, W...> ;Clinical Cancer Research. 2013 May 15
30 citations
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung ...
Chandra P. Belani, John Nemunaitis, Abraham Chachoua, Peter D Eisenberg, Luiz E Raez, J Daniel Cuevas, Cecile B. Mather, Rebecca J. Benner, Sandra J. Meech> ;Cancer Biology & Therapy. 2013 May 10
337 citations
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea L. Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein...> ;Journal of Clinical Oncology. 2013 Jan 10
179 citations
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Eric B. Haura, Alejandro D. Ricart, Timothy G. Larson, Philip J. Stella, Lyudmila Bazhenova, Vincent A. Miller, Roger B. Cohen, Peter D. Eisenberg, Paulina Selaru, Kei...> ;Clinical Cancer Research. 2010 Apr 15
48 citations
Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and ...
Daniel D. Karp, Michael Pollak, Roger B. Cohen, Peter D. Eisenberg, Paul Haluska, Donghua Yin, Allan Lipton, Laurence M. Demers, Kim Leitzel, Mary L. Hixon, Leon W.M.M...> ;Journal of Thoracic Oncology. 2009 Nov 1
11 citations
Evolution and elements of the quality oncology practice initiative measure set.
Michael N. Neuss, Joseph O. Jacobson, Kristen K. McNiff, Pamela Kadlubek, Peter D. Eisenberg, Joseph V. Simone> ;Cancer Control. 2009 Oct 1
205 citations
Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Local...
Daniel D. Karp, Luis Paz-Ares, Silvia Novello, Paul Haluska, Linda L. Garland, Felipe Cardenal, L. Johnetta Blakely, Peter D. Eisenberg, Corey J. Langer, George R. Blu...> ;Journal of Clinical Oncology. 2009 May 20
58 citations
Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer
Anthony L.A. Fields, Alan Keller, Lee S. Schwartzberg, Stephen A. Bernard, Carl Kardinal, Alan R. Cohen, Joe Schulz, Peter D. Eisenberg, John K. Forster, Paul Wissel> ;Journal of Clinical Oncology. 2009 Apr 20
54 citations
Measuring Supportive Care in Medical Oncology Practice: Lessons Learned From the Quality Oncology Practice Initiative
Kristen McNiff, Michael N. Neuss, Joseph O. Jacobson, Peter D. Eisenberg, Pamela Kadlubek, Joseph V. Simone> ;Journal of Clinical Oncology. 2008 Aug 10
High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC.
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Gualberto A, Langer CJ> ;J. Clin. Oncol.. 2008-05-20
379 citations
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline...
Harold J. Burstein, Anthony D. Elias, Hope S. Rugo, Melody A. Cobleigh, Antonio C. Wolff, Peter D. Eisenberg, Mary Lehman, Bonne J. Adams, Carlo L. Bello, Samuel E. De...> ;Journal of Clinical Oncology. 2008 Apr 10
88 citations
Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative.
Joseph O. Jacobson, Michael N. Neuss, Kristen K. McNiff, Pamela Kadlubek, Leroy R. Thacker, Frank Song, Peter D. Eisenberg, Joseph V. Simone> ;Journal of Clinical Oncology. 2008 Apr 10
12 citations
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplati...
Roger B. Cohen, Corey J. Langer, George R. Simon, Peter D. Eisenberg, John D. Hainsworth, Stefan Madajewicz, Thomas Michael Cosgriff, Kristen J. Pierce, Huiping Xu, K....> ;Cancer Chemotherapy and Pharmacology. 2007 Jun 1
227 citations
Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings
Lorenzo Cohen, Carl de Moor, Peter Eisenberg, Eileen E. Ming, Henry Hu> ;Supportive Care in Cancer. 2007 May 1
96 citations
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.
Jørn Herrstedt, Hyman B. Muss, David Warr, Paul J. Hesketh, Peter D. Eisenberg, Harry Raftopoulos, Steven M. Grunberg, Munir Gabriel, Anthony Rodgers, Carolyn M. Husta...> ;Cancer. 2005 Oct 1
191 citations
A Process for Measuring the Quality of Cancer Care: The Quality Oncology Practice Initiative
Michael N. Neuss, Christopher E. Desch, Kristen K. McNiff, Peter D. Eisenberg, Dean H. Gesme, Joseph O. Jacobson, Mohammad Jahanzeb, Jennifer J. Padberg, John M. Raine...> ;Journal of Clinical Oncology. 2005 Sep 1
Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC).
Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CM> ;J. Clin. Oncol.. 2005-06-01
353 citations
Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemo...
David Warr, Paul J. Hesketh, Richard J. Gralla, Hyman B. Muss, Jørn Herrstedt, Peter D. Eisenberg, Harry Raftopoulos, Steven M. Grunberg, Munir Gabriel, Anthony Rodger...> ;Journal of Clinical Oncology. 2005 Apr 20
A practice-based, voluntary program for promoting excellence in cancer care: A pilot study of feasibility, cost and preliminary results.
Desch CE, Eisenberg P, Gesme D, Jacobson J, Jahanzeb M, Neuss M, Padberg J, Rainey J, Simone J> ;J. Clin. Oncol.. 2004-07-15
Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC).
Cohen RB, Simon G, Langer CJ, Schol JR, McHale J, Eisenberg P, Hainsworth JD, Liau KF, Healey D> ;J. Clin. Oncol.. 2004-07-15
Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients.
Warr DG, Eisenberg P, Hesketh PJ, Gralla RJ, Muss H, Raftopolous H, Gabriel M, Rodgers A, Hustad CM, Skobieranda F> ;J. Clin. Oncol.. 2004-07-15
A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study.
Jacobs AD, Burris HA, Rivkin S, Ritch PS, Eisenberg PD, Mettinger KL> ;J. Clin. Oncol.. 2004-07-15
Join now to see all

Abstracts/Posters

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis
Peter Eisenberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Should Oncology Practices Be Required to Publicly Report Measures of End-of-Life Care Intensity?July 26th, 2019
ASCO Unveils Major Expansion of Big-Data InitiativeJune 6th, 2016
Soon-Shiong's Cancer MoonShot Forms Pediatric PartnershipsFebruary 18th, 2016
Join now to see all